Diabetes care最新文献

{"title":"Ultra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion.","authors":"Jennifer K Leohr, Alexander Abitbol, Lauren V Turner, Elizabeth Smith LaBell, Aritra Ghosh, David E Coutant, Michael C Riddell","doi":"10.2337/dc25-2294","DOIUrl":"10.2337/dc25-2294","url":null,"abstract":"<p><strong>Objective: </strong>To compare the glycemic response and pharmacokinetics (PK) of ultra-rapid lispro (URLi) versus lispro during manual basal rate reductions (BRRs) before exercise with conventional continuous subcutaneous insulin infusion (CSII) in active adults with type 1 diabetes.</p><p><strong>Research design and methods: </strong>This study was a double-blind, four-period, crossover, randomized controlled trial. Exercise (60 min walking at 45-55% VO2max) was performed 4 h after a standardized meal, with either a 50% (-60 min) or 100% (-15 min) BRR before exercise using URLi or lispro. The primary end point was the change in glucose during exercise, and insulin lispro PK was the secondary end point.</p><p><strong>Results: </strong>Twenty-five participants (mean ± SD age 36.7 ± 10.3 years; mean ± SD HbA1c 50.4 ± 8.5 mmol/mol [6.76 ± 0.8%]; 48% female) completed the study. URLi significantly attenuated the reduction in glucose level compared with lispro during both the 50% BRR (-26.8 ± 37 vs. -39.0 ± 39 mg/dL; P < 0.05) and the 100% BRR (-46.9 ± 32 vs. -60.5 ± 39 mg/dL; P < 0.01). Circulating insulin lispro concentrations rose in the first 15 min of exercise, but maximum concentration was lower with URLi versus lispro within each BRR strategy. Numerically less hypoglycemia was observed during exercise with URLi (6%) compared with lispro (16%). Following a postexercise meal, faster insulin absorption of URLi resulted in an earlier postprandial glucose lowering compared with lispro.</p><p><strong>Conclusions: </strong>Using URLi in conventional CSII pump therapy provides more effective BRRs prior to exercise compared with lispro, with fewer hypoglycemic events in active adults with type 1 diabetes.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"1185-1193"},"PeriodicalIF":16.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13294794/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147517680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep Optimization to Improve Glycemic Targets in Adults With Type 1 Diabetes: A Randomized Controlled Parallel Intervention Trial.","authors":"Pamela Martyn-Nemeth, Jennifer Duffecy, Alana D Steffen, Kelly Glazer Baron, Laurie Quinn, Larisa Burke, Margaret H Clark Withington, Bernardo Loiacono, Mary Takgbajouah, Ghada Abu Irsheed, Rosanne I Perez, Minsun Park, Adam H Saleh, Dan Mihailescu, Seok Jin Hong, Sarida Pratuangtham, Justine Kessler, Sirimon Reutrakul","doi":"10.2337/dc26-0273","DOIUrl":"10.2337/dc26-0273","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of a sleep intervention (Sleep-Opt) compared with an attention control intervention (Healthy Living) on glycemic targets and psychological outcomes in adults with type 1diabetes (T1D).</p><p><strong>Research design and methods: </strong>Adults with T1D and short (<6.5 h/night) or irregular (variability of sleep duration ≥1 h) sleep were randomly assigned to either the Sleep-Opt (n = 73) or Healthy Living control (n = 71) intervention, both of which were remotely delivered in eight sessions for 12 weeks. Primary (A1C, continuous glucose monitoring [CGM], and objective sleep) and secondary (psychological and subjective sleep) outcomes were collected at baseline and 6, 12, and 24 weeks, with 12 weeks being a primary end point.</p><p><strong>Results: </strong>A1C and CGM parameters at 12 weeks indicated no significant differences between groups. Sleep duration increased at 6 weeks in both groups, but no significant differences were observed between groups at any time point. Sleep-Opt participants had reduced diabetes distress (median difference -0.18 [95% CI -0.35, -0.01]) and improved subjective sleep quality (-0.96 [-0.17, -0.23]) compared with the Healthy Living group at 6 weeks but not at other time points. A significant interaction was found suggesting the effect of the intervention depended on baseline A1C level. At 12 weeks, the Sleep-Opt group with baseline A1C ≥7% had a lower A1C level than the Healthy Living group (marginal mean -0.32% [95% CI -0,64%, -0.005%]; -3.5 [95% CI -7.0, -0.1] mmol/mol; P = 0.047).</p><p><strong>Conclusions: </strong>Sleep-Opt did not improve glycemic targets or sleep parameters, although sleep improved in both intervention groups. Glycemic benefits were observed in participants with suboptimal A1C, suggesting a possible role of sleep intervention in this patient group.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"1270-1279"},"PeriodicalIF":16.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13294793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147965943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Dose Antithymocyte Globulin in Type 1 Diabetes: Real-World Exploratory Observation of C-Peptide by Modified Quantitative Response (mQR).","authors":"David Weber, Joshua Modeste, Sarah Peeling, Timothy P Foster, Brittany S Bruggeman, Laura M Jacobsen, Desmond A Schatz, Michael J Haller","doi":"10.2337/dc26-0223","DOIUrl":"10.2337/dc26-0223","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the real-world feasibility and efficacy of low-dose antithymocyte globulin (ATG) by an exploratory modified quantitative response (mQR) of C-peptide in type 1 diabetes.</p><p><strong>Research design and methods: </strong>Individuals with stage 2 (n = 6) or stage 3 (n = 33) diabetes were treated clinically with low-dose ATG (2.5 mg/kg) and asked to obtain C-peptide via a commercial laboratory 90 min postconsumption of 6 mL/kg Boost. Thirty individuals (77%) completed 1 year of follow-up, with 22 (73% of those) providing pre-ATG and 1-year-post-ATG C-peptides. Area under the curve C-peptide was estimated from 90-min values to calculate mQR.</p><p><strong>Results: </strong>In the 22 evaluable patients, average mQR at 1 year was 0.072. Average HbA1c decreased from 7.1% (54 mmol/mol) to 6.0% (42 mmol/mol). There were 15 responders (+mQR) and 7 nonresponders (-mQR). There were no unexpected side effects.</p><p><strong>Conclusions: </strong>C-peptide mQR was feasible and produced expected responder frequencies following low-dose ATG in a clinical practice setting.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"1258-1261"},"PeriodicalIF":16.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13294778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Look AHEAD Research Program: A 25-Year Retrospective From the Perspective of Geroscience.","authors":"Mark A Espeland, Charles T Semelka, Stephen B Kritchevsky, Joni K Evans, Anne B Newman","doi":"10.2337/dci25-0126","DOIUrl":"10.2337/dci25-0126","url":null,"abstract":"<p><p>The 10-year Action for Health in Diabetes (Look AHEAD) clinical trial compared a multidomain intensive lifestyle intervention to a diabetes support and education program with respect to major cardiovascular disease events (primary outcome) and other diabetes- and obesity-related outcomes. Follow-up of the cohort continues to add other aging-related outcomes and conditions to identify the long-term consequences of factors related to lifestyle and medical care. In this transition to a study of aging among individuals at risk for accelerated aging due to type 2 diabetes and overweight or obesity, the investigators have retrospectively reframed the study using the perspective of geroscience. This perspective strengthens the importance of lifestyle changes as a core component for medical care for these individuals to slow biological aging.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"1159-1162"},"PeriodicalIF":16.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13294790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146032153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous Glucose Monitoring and Mortality Risk Among U.S. Veterans Receiving Dialysis With Diabetes.","authors":"Yoko Narasaki, Kamyar Kalantar-Zadeh, Yaara Zisman-Ilani, David C Klonoff, Csaba P Kovesdy, Zhaoping Li, Anna Jin, Susan Crowley, Justin M Belcher, Patrick Gee, Greg E Gin, Mark Jordan, Amy S You, Andrea C Daza, Ramy Hanna, Danh V Nguyen, Connie M Rhee","doi":"10.2337/dc26-0004","DOIUrl":"10.2337/dc26-0004","url":null,"abstract":"<p><strong>Objective: </strong>Patients receiving dialysis who have diabetes have a high burden of dysglycemia. Whereas traditional glycemic markers have limited accuracy and convenience in dialysis, continuous glucose monitoring (CGM) provides automated, less invasive, and more comprehensive glycemic data than do conventional measures. However, it remains unclear whether CGM is associated with improved clinical outcomes in patients undergoing dialysis.</p><p><strong>Research design and methods: </strong>We examined the association between CGM use versus non-CGM use and survival among U.S. veterans receiving dialysis who also have diabetes, using linked national Veterans Affairs, U.S. Renal Data System, and Medicare data. We examined data from veterans undergoing dialysis and with diabetes with incident CGM use (newly prescribed CGM) versus non-CGM use over the period January 2012 to December 2023 matched by propensity score (PS) to address confounding by indication and who were followed for all-cause mortality events through February 2025. Associations of CGM use versus non-CGM use with death were evaluated using complete case analysis and multiple imputation.</p><p><strong>Results: </strong>Among 2,008 patients in the complete case analysis cohort, CGM use was associated with a lower mortality risk in PS-matched unadjusted and doubly adjusted Cox models (reference: non-CGM use; hazard ratio [HR] 0.86 [95% CI 0.76, 0.98]; and 0.83 [95% CI 0.75, 0.92], respectively). Among 3,088 patients in the multiple imputation cohort, CGM use was also associated with greater survival in PS-matched unadjusted and doubly adjusted Cox models (HR 0.88 [95% CI 0.77, 0.99]; and 0.84 [95% CI 0.73, 0.96], respectively).</p><p><strong>Conclusions: </strong>In veterans receiving dialysis who also had diabetes, incident CGM use was associated with better survival versus non-CGM use. Further studies are needed to determine underlying mechanisms and the impact of CGM on other dialysis outcomes.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"1285-1293"},"PeriodicalIF":16.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13294783/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148145862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Comment on Huttasch et al. Increased Early Postprandial Glucagon Concentrations in Humans With Newly Diagnosed Type 2 Diabetes and Steatotic Liver Disease.","authors":"Maximilian Huttasch, Michael Roden","doi":"10.2337/dci26-0069","DOIUrl":"10.2337/dci26-0069","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":"49 7","pages":"e129-e130"},"PeriodicalIF":16.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13294788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148304463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationships Between Regional and Ectopic Adiposity and Insulin Sensitivity in Early and Late Pregnancy.","authors":"Jonathan Q Purnell, Nicole Marshall, Melanie Francisco, Michael Leo, William D Rooney, Eric Baetscher, Antonio Frias, Amy Valent, Patrick Catalano, Janet King, Kimberly K Vesco","doi":"10.2337/dc25-2081","DOIUrl":"10.2337/dc25-2081","url":null,"abstract":"<p><strong>Objective: </strong>To determine relationships between measurements of total body, visceral, and ectopic (liver, skeletal muscle) fat with insulin sensitivity in pregnancy.</p><p><strong>Research design and methods: </strong>Pregnant women of varying prepregnancy weights were prospectively studied in early (n = 59) and late (n = 47) gestation. At each visit, participants underwent body composition measurements including fat mass (FM), fat-free mass (FFM), abdominal subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), ectopic lipid amounts in liver (intrahepatic lipid [IHL]) and calf skeletal muscle (intramyocellular lipid [IMCL] and extramyocellular lipid), and hyperinsulinemia-euglycemic clamp to determine insulin sensitivity (Rd), endogenous glucose production (EGP), hepatic insulin sensitivity index (HISI), and free fatty acid (FFA) levels.</p><p><strong>Results: </strong>In early pregnancy, Rd ([mg/kg FFM/min]/µIU/mL) inversely correlated (P values <0.05) with BMI, FM, SAT, VAT, IHL, IMCL, and FFA. HISI inversely correlated (P values <0.05) with BMI, FM, SAT, VAT, IMCL, and FFA but not with IHL. In late pregnancy, however, neither EGP ([mg/kg FFM/min]/µIU/mL) nor Rd correlated with regional or ectopic fat measures, but HISI remained inversely correlated with BMI, FM, SAT, VAT, and IMCL. Early-pregnancy IHL levels did not predict late-pregnancy insulin sensitivity. Pregnant women with prepregnancy obesity were more insulin resistant but gained less gestational weight, VAT, and SAT, and experienced less decline in insulin sensitivity, than normal prepregnancy weight women.</p><p><strong>Conclusions: </strong>Insulin resistance in early pregnancy is strongly associated with total, regional, and ectopic adiposity. However, in late pregnancy, factors other than regional and ectopic adiposity predominately influence insulin sensitivity. Prepregnancy weight categories proportionately alter gestational weight gain, adiposity distribution, and glucometabolic responses.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"1175-1184"},"PeriodicalIF":16.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13108613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147291971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Clinical Manifestations and Islet Autoantibodies by Age in Adult-Onset Type 1 Diabetes.","authors":"Kagan E Karakus, Maia G Clayton, Erin E Baschal, Kristen A McDaniel, Liping Yu, Zehra Haider, Sarit Polsky, Halis K Akturk, Peter A Gottlieb, Satish K Garg, Aaron W Michels","doi":"10.2337/dc25-2660","DOIUrl":"10.2337/dc25-2660","url":null,"abstract":"<p><strong>Objective: </strong>Adult-onset type 1 diabetes is not well characterized, especially after 40 years of age, and is commonly misdiagnosed as type 2 diabetes. We evaluated the differences in clinical presentation, islet autoantibodies, and HLA genetics between pediatric- and adult-onset type 1 diabetes.</p><p><strong>Research design and methods: </strong>Individuals who were newly diagnosed with type 1 diabetes were tested for islet autoantibodies within 1 year of diagnosis in this retrospective study. Islet autoantibodies against GAD, insulin, islet antigen 2, and zinc transporter 8 were measured using fluid-phase radiobinding assays. High-resolution HLA class I (n = 655) and II (n = 1,196) typing was performed in a subset of participants.</p><p><strong>Results: </strong>In total, 414 adults (aged ≥20 years) and 2,000 children were included. Adults were aged 20-76 years and had a mean BMI of 23.5 ± 4.7 kg/m2 at onset. Compared with children, adults presented with diabetic ketoacidosis (DKA) less frequently (32.6% vs. 56.0%; P < 0.001) and with slightly lower HbA1c values (11.3% ± 2.6% vs. 12.0% ± 2.4%; P < 0.001). Notably, adults older than 40 years (n = 84) presented with DKA only 13.1% of the time. Adults more often presented with zero or one islet autoantibodies compared with children (43.0% vs. 20.2%; P < 0.001). There were no differences in high-risk HLA haplotypes between adults and children (DR4-DQ8: 57.1% vs. 63.7%; P = 0.060; DR3-DQ2: 43.6% vs. 46.1%; P = 0.482).</p><p><strong>Conclusions: </strong>Adult-onset type 1 diabetes is characterized by a reduced frequency of DKA and by fewer total islet autoantibodies. Our findings can help in the accurate diagnosis of type 1 diabetes in adults.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"1194-1201"},"PeriodicalIF":16.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13294791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147597033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes and Vitiligo.","authors":"Jinghe Li, Xinyi Shao, Yi Ou, Zhaofu Tan, Tingqiao Chen, Genlong Bai, Jin Chen, Jun Shirakawa, Jingbo Zhang","doi":"10.2337/dc26-0488","DOIUrl":"10.2337/dc26-0488","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"e121-e123"},"PeriodicalIF":16.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13294776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147719187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.","authors":"Henrik Maagensen, Stine O Høyerup, Johanne S Jensen, Anne C B Thuesen, Julie L Forman, Henrik H Thomsen, Henrik Vestergaard, Filip K Knop, Torben Hansen, Sofie Hædersdal, Julie Støy, Tina Vilsbøll","doi":"10.2337/dc25-2572","DOIUrl":"10.2337/dc25-2572","url":null,"abstract":"<p><strong>Objective: </strong>Maturity-onset diabetes of the young (MODY) caused by pathogenic variants in HNF1A is a common form of monogenic diabetes. Sulfonylurea drugs are considered first-line treatment of HNF1A-MODY (MODY3), but intensified treatment is often needed. HNF1A encodes a transcription factor involved in the regulation of the sodium-glucose cotransporter 2 (SGLT2). Accordingly, the glucose-lowering efficacy of SGLT2 inhibitors in HNF1A-MODY is questionable. Here, we assess the glucose-lowering effect of the SGLT2 inhibitor empagliflozin as an add-on for treatment of individuals with HNF1A-MODY.</p><p><strong>Research design and methods: </strong>MOD3ST-TRIAL was a randomized, double-blind, placebo-controlled crossover trial. Adults with HNF1A-MODY treated with at least one glucose-lowering drug were randomized to be treated with empagliflozin 25 mg for 4 weeks followed by a 2-week washout period and then received placebo for 4 weeks or the opposite sequence. The primary outcome was mean glucose concentration assessed by 10 days of continuous glucose monitoring (CGM).</p><p><strong>Results: </strong>Nineteen individuals were randomized and 18 participants (n = 10 women [56%]; median [Q1, Q3] HbA1c 7.5% [7.0, 8.4] or 58 [53, 68] mmol/mol, mean [SD] CGM glucose concentration 10.4 [2.5] mmol/L) completed the study. Compared with placebo, empagliflozin lowered the mean glucose level 2.3 mmol/L (95% CI 1.3 to 3.3; P = 0.0001). There were no significant differences in hypoglycemic outcomes. Adverse events were generally mild and transient, and no severe adverse events or study drug discontinuations were attributable to empagliflozin.</p><p><strong>Conclusions: </strong>Empagliflozin used for 4 weeks in adjunction with other glucose-lowering treatments markedly improved glycemia compared with placebo in individuals with HNF1A-MODY without significantly increasing risk of hypoglycemia or unexpected adverse effects.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"1166-1174"},"PeriodicalIF":16.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13294792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145960904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}